These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 8546391)
1. Obtaining marketing authorization for nucleic acid vaccines in the European Union. Cichutek K Ann N Y Acad Sci; 1995 Nov; 772():178-85. PubMed ID: 8546391 [TBL] [Abstract][Full Text] [Related]
3. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements. Robertson JS; Cichutek K Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824 [TBL] [Abstract][Full Text] [Related]
4. Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. Johnson PR; Montefiori DC; Goldstein S; Hamm TE; Zhou J; Kitov S; Haigwood NL; Misher L; London WT; Gerin JL AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1501-5. PubMed ID: 1466990 [No Abstract] [Full Text] [Related]
5. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664 [TBL] [Abstract][Full Text] [Related]
6. Regulatory issues in the use of DNA vaccines. Minor PD Ann N Y Acad Sci; 1995 Nov; 772():170-7. PubMed ID: 8546390 [No Abstract] [Full Text] [Related]
7. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials]. Dejas-Eckertz P; Schäffner G Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253 [TBL] [Abstract][Full Text] [Related]
8. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828 [TBL] [Abstract][Full Text] [Related]
9. Assuring the safety and efficacy of DNA vaccines. Griffiths E Ann N Y Acad Sci; 1995 Nov; 772():164-9. PubMed ID: 8546389 [No Abstract] [Full Text] [Related]
10. Retroviral vectors for HIV immunotherapy. Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383 [No Abstract] [Full Text] [Related]
11. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
12. Simian immunodeficiency virus DNA vaccine trial in macaques. Robinson HL; Lu S; Mustafa F; Johnson E; Santoro JC; Arthos J; Winsink J; Mullins JI; Montefiori D; Yasutomi Y Ann N Y Acad Sci; 1995 Nov; 772():209-11. PubMed ID: 8546394 [No Abstract] [Full Text] [Related]
13. Regulatory issues relating to the use of recombinant vectors in production of human vaccines. Marcus-Sekura CJ Dev Biol Stand; 1994; 82():107-12. PubMed ID: 7958464 [TBL] [Abstract][Full Text] [Related]
14. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502 [TBL] [Abstract][Full Text] [Related]
15. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434 [TBL] [Abstract][Full Text] [Related]
16. [Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th Law Amending the German Drug Law]. Geisler I; Hofmann HP; Nickel L Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):141-6. PubMed ID: 15726454 [TBL] [Abstract][Full Text] [Related]
17. The European hospital exemption clause-new option for gene therapy? Buchholz CJ; Sanzenbacher R; Schüle S Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961 [TBL] [Abstract][Full Text] [Related]
18. Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. Miller MD; Gould-Fogerite S; Shen L; Woods RM; Koenig S; Mannino RJ; Letvin NL J Exp Med; 1992 Dec; 176(6):1739-44. PubMed ID: 1460429 [TBL] [Abstract][Full Text] [Related]
19. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726 [TBL] [Abstract][Full Text] [Related]
20. Nucleic acid vaccination against virally induced tumors. Bright RK; Shearer MH; Kennedy RC Ann N Y Acad Sci; 1995 Nov; 772():241-51. PubMed ID: 8546399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]